About: The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 26 October 2010

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) article scientifique publié en 2010 (fr) наукова стаття, опублікована в жовтні 2010 (uk) im Oktober 2010 veröffentlichter wissenschaftlicher Artikel (de) scientific article published on 26 October 2010 (en) artículu científicu espublizáu n'ochobre de 2010 (ast)
publication date	wds:Q57272556-19AA8F14-A0E1-4901-B764-0F7391929BAE
publication date	2010-10-26 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q57272556-5DA30509-962B-4CBE-A4F3-32FEF6237049
language of work or name	English
author name string	wds:Q57272556-08FF1B07-0221-4D55-8AAE-ABED7EC4481E wds:Q57272556-21D58FAC-AD25-4B9B-8A19-8AC1E4FF5F2E wds:Q57272556-2E36B07A-8D5A-44CC-BF44-08C53302ABD6 wds:Q57272556-56614A1E-876C-4CCC-AF59-3CE268D60A56 wds:Q57272556-9D85C051-A2BC-40CE-A554-D9A51BD59D20
author name string	H Miles Prince Hang Quach David S Ritchie Andy K Hsu Tsin Tai
rdfs:label	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (en) The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (nl)
skos:prefLabel	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (en) The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (nl)
name	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (en) The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (nl)
author	wds:Q57272556-0FD53DD9-0573-4E85-A56D-D66DE2445E91 wds:Q57272556-267CCF16-F70C-4E96-8635-296882C98F45 wds:Q57272556-89F840DE-C4BA-43FC-B074-483B4404800E wds:Q57272556-CF3F9F72-25EC-4DBA-B32E-14274303E3BC
author	Mark J. Smyth Joseph A. Trapani Paul Neeson Simon Harrison
title	wds:Q57272556-B060D013-6692-49E7-88C1-9082759A7074
title	The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy (en)
page(s)	wds:Q57272556-D6CFA9F6-C476-49EA-91E2-4C320CA8D94F
page(s)	1605-1613
instance of	wds:Q57272556-AA3ADCEC-6247-4BAB-8E03-031E0124BA39
instance of	scholarly article
main subject	wds:Q57272556-758B8079-BA8C-40B7-8B27-09843AAC2786 wds:Q57272556-A1719735-1B3D-4AA3-9ECC-9E1850B8A9C9
main subject	wd:Q422252 cell function
PubMed ID	wds:Q57272556-97E783D4-66AE-4341-9560-6CBB1D018B61
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/20978269
PubMed ID	20978269
published in	wds:Q57272556-BB59129B-1033-40A4-94D7-C0318603B568
published in	Blood
issue	wds:Q57272556-51BF522A-773A-4FDF-A728-246F737E758F
volume	wds:Q57272556-6C22E167-B9D5-473A-9343-2E55DC3C2B15
issue	5
volume	117
DOI	wds:Q57272556-C2443C29-8532-4B9A-ACD5-7E8A25C4B835
DOI	http://dx.doi.org/10.1182/BLOOD-2010-04-278432
DOI	10.1182/BLOOD-2010-04-278432
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q57272556
is cites work of	Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection Predictors of survival to orthotopic heart transplant in patients with light chain amyloidosis Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression Immunotherapy response assessment in neuro-oncology: a report of the RANO working group Opportunities and limitations of natural killer cells as adoptive therapy for malignant disease Dexamethasone exerts profound immunologic interference on treatment efficacy for recurrent glioblastoma Lenalidomide augments actin remodeling and lowers NK-cell activation thresholds Clinical regressions and broad immune activation following combination therapy targeting human NKT cells in myeloma Thalidomide-analogue biology: immunological, molecular and epigenetic targets in cancer therapy. Molecular mechanisms of natural killer cell activation in response to cellular stress Natural killer cell biology: an update and future directions Expansion of polyfunctional HIV-specific T cells upon stimulation with mRNA electroporated dendritic cells in the presence of immunomodulatory drugs IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma A Phase I Trial of the Anti-KIR Antibody IPH2101 and Lenalidomide in Patients with Relapsed/Refractory Multiple Myeloma. Flow cytometry-based enumeration and functional characterization of CD8 T regulatory cells in patients with multiple myeloma before and after lenalidomide plus dexamethasone treatment. Expanding role of lenalidomide in hematologic malignancies Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets Progress in novel cellular therapy options for chronic lymphocytic leukemia: the M D Anderson perspective Understanding of molecular mechanisms in natural killer cell therapy The role of natural killer cells in immunity against multiple myeloma Targeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical Approaches Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients Lenalidomide alone or lenalidomide plus dexamethasone significantly inhibit IgG and IgM in vitro... A possible explanation for their mechanism of action in treating multiple myeloma Immunomodulatory Drugs in Multiple Myeloma: Mechanisms of Action and Clinical Experience Myeloma skews regulatory T and pro-inflammatory T helper 17 cell balance in favor of a suppressive state. Molecular action of lenalidomide in lymphocytes and hematologic malignancies Combination immune therapies to enhance anti-tumor responses by NK cells. Macrophages in multiple myeloma: emerging concepts and therapeutic implications Trial Watch: Lenalidomide-based immunochemotherapy Association of Th1 and Th2 cytokines with transient inflammatory reaction during lenalidomide plus dexamethasone therapy in multiple myeloma. Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients Assessment of Brain Tumor Response: RANO and Its Offspring Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling. Lenalidomide in diffuse large B-cell lymphoma Natural killer T cell defects in multiple myeloma and the impact of lenalidomide therapy Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma Lenalidomide in multiple myeloma: Current status and future potential Induction of potent NK cell-dependent anti-myeloma cytotoxic T cells in response to combined mapatumumab and bortezomib

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 193 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software